CRISPR-SONIC: Targeted somatic oncogene knock-in enables rapid in vivo cancer modeling

16Citations
Citations of this article
53Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

CRISPR/Cas9 has revolutionized cancer mouse models. Although loss-of-function genetics by CRISPR/Cas9 is well-established, generating gain-of-function alleles in somatic cancer models is still challenging because of the low efficiency of gene knock-in. Here we developed CRISPR-based Somatic Oncogene kNock-In for Cancer Modeling (CRISPR-SONIC), a method for rapid in vivo cancer modeling using homology-independent repair to integrate oncogenes at a targeted genomic locus. Using a dual guide RNA strategy, we integrated a plasmid donor in the 3′-UTR of mouse β-actin, allowing co-expression of reporter genes or oncogenes from the β-actin promoter. We showed that knock-in of oncogenic Ras and loss of p53 efficiently induced intrahepatic cholangiocarcinoma in mice. Further, our strategy can generate bioluminescent liver cancer to facilitate tumor imaging. This method simplifies in vivo gain-of-function genetics by facilitating targeted integration of oncogenes.

Cite

CITATION STYLE

APA

Mou, H., Ozata, D. M., Smith, J. L., Sheel, A., Kwan, S. Y., Hough, S., … Xue, W. (2019). CRISPR-SONIC: Targeted somatic oncogene knock-in enables rapid in vivo cancer modeling. Genome Medicine, 11(1). https://doi.org/10.1186/s13073-019-0627-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free